We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is proposing to reclassify two high-risk, class III devices — optical diagnostic devices for melanoma detection and electrical impedance spectrometers — into class II (special controls) subject to 510(k) clearance. Read More
Medical Device Single Audit Program (MDSAP) regulatory authorities (RAs) have extended the program’s remote audit arrangements until Sept. 30. Read More
The Office of Management and Budget has belatedly posted its Spring regulatory agenda for the federal government, including the following medical device-related proposed and final rules that the FDA is aiming to release. Read More
Sunnyvale, Calif.-based Aerin Medical’s VivAer Stylus treatment for nasal airway obstruction due to nasal valve collapse showed positive four-year results in a postmarket study. Read More
Canadian diagnostics company Nanostics released interim trial data showing its ClarityDX prostate test is 147 percent more specific than the prostate-specific antigen (PSA) blood test for predicting clinically significant prostate cancer. Read More